Advancing digital healthcare: Our Life Science fund’s latest HealthTech investments

Our Life Science team has been active during the past months. During the first quarter, four new investments have already been made, and we are now introducing three of the fund’s investments, which are part of the fund’s digital health portfolio. All investments are syndicated with other specialist investors. 

The power of syndication in the Nordics 

“Syndication will continue to be the dominant market trend within life sciences among investors in the Nordics. Even while globally there’s talk about syndication being passé because of ever-bigger new funds. There aren’t too many active life science funds in the Nordics, and they aren’t too big.” 

Pekka Simula, Partner, Innovestor Life Science Fund

Overall, our team emphasizes the need for more intensive collaboration between funds, especially in this market. It takes deep expertise and deep pockets to support solutions from early development through regulatory approvals and commercialization. 

“Even though times are hard, it is fantastic to see that the level of science is high everywhere in the Nordics. The Nordics stand out from the rest of the world. Our new investments are also good demonstrations of this,” Pekka continues.

Spotlight on new investments 

Vaalia Health 

Vaalia Health aims to improve treatment adherence of oral cancer drugs, a significant and growing cancer treatment modality. Based on several studies, drug adherence is variable but poor, leading to early treatment discontinuations and suboptimal treatment outcomes. Vaalia Health, founded by a serial healthcare entrepreneur team, aims to tackle the most critical connection for during-treatment support in the US market: the connection between the patient and the specialty pharmacy. 

Co-investors in Pre-Seed: Inventure, Calm/Storm Ventures, Noaber Ventures, US angel syndicate 

Deep Measures 

DEEP Measures facilitates the use of digital endpoints in clinical trials. The €50 billion clinical trial market wastes significant time and money in suboptimal clinical trials that acquire sporadic and subjective patient data. State-of-the art technologies are not used due to regulatory barriers. DEEP platform, which enables precompetitive collaboration of pharmaceutical companies and streamlined communication with regulators, has already secured paying customers from Big Pharma. 

Co-investors: Lifeline Ventures, Johnson Johnson 

CardioSignal by Precordior 

Precordior is the leader in gyrocardiography, a non-invasive way to assess heart motions using a gyroscope, turning any modern mobile phone into a medical device. Scientific research of the team has shown that analyzing the rotational movement of the chest is surprisingly powerful for cardiac disease detection and diagnostics. The company’s product Cardio Signal works on a standard smartphone with no additional equipment needed, and is already in early commercial stage. 

Co-investors: DigiTx, Sandwater,, Cardio By Design 

More info about the Life Science fund, our team, and fund’s portfolio: